Biotech News

TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update

TG Therapeutics (TGTX)TG TherapeuticsEarnings

CONFERENCE CALL TO BE HELD MONDAY, NOVEMBER 9, 2026, AT 8:30 AM ET NEW YORK --(BUSINESS WIRE)--Nov. 2, 2026-- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 9, 2026, at 8:30 AM ET to discuss results for the third quarter 2026 and to

Related news

TG Therapeutics

B-Cell-Directed Therapies TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program. BRIUMVI BRIUMVI, or ublituximab, is a glycoengineered CD20...

Recent company news

Stock data

Close
64.88 USD
Market cap
5.61B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States